InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.50.

Several equities research analysts recently commented on IFRX shares. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down previously from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Guggenheim raised their price objective on InflaRx from $10.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Wall Street Zen cut InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Raymond James Financial reaffirmed an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of InflaRx in a research note on Tuesday, December 30th.

InflaRx Stock Performance

InflaRx stock opened at $0.89 on Thursday. The stock has a market capitalization of $60.07 million, a P/E ratio of -1.32 and a beta of 1.46. The company’s fifty day moving average price is $1.03 and its 200 day moving average price is $1.16. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.77.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. Sell-side analysts predict that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE purchased a new stake in shares of InflaRx in the 3rd quarter valued at about $3,316,000. Woodline Partners LP purchased a new position in InflaRx during the 1st quarter worth $766,000. Adage Capital Partners GP L.L.C. acquired a new position in InflaRx in the second quarter valued at $262,000. Squarepoint Ops LLC raised its holdings in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after buying an additional 42,489 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its stake in shares of InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after buying an additional 17,056 shares during the period. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.